Prescribing information

 

   

Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis in adults who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated CRP and/or MRI evidence in adults who have responded inadequately to NSAIDs.

About BADBIR

BADBIR is one of the world’s largest prospective registries for psoriasis, with over 160 hospital sites in the UK and ROI, evaluating the long-term safety and effectiveness of biologic treatments.1–3

Analysis using the BADBIR data showed that in the real-world, your psoriasis patients can achieve high levels of drug survival and skin clearance with Cosentyx.1,3

Image showing High levels of drug survival over 2 years in PsO patients, with or without PsA from an Analysis by the BADBIR group
Image showing High levels of skin clearance at years 1 and 2 from analysis by Novartis using BADBIR data
 

Cosentyx had a higher survival functional than adalimumab at all time points and across all reasons for discontinuation over 2 years1

Graph showing Cosentyx had a higher survival functional than adalimumab at all time points and across all reasons for discontinuation over 2 years with icon of Analysis from the BADBIR group

Adapted from Yiu ZZN et al. 2020.1

Reasons for discontinuation were classified as ineectivenessand adverse events.

 

What did the analysis by Novartis using BADBIR data show?

You can be confident your patients can stay on Cosentyx

Watch now: a 2-minute summary of this data

 

 

Click here for Cosentyx®(secukinumab) prescribing information

This summary demonstrates how you can achieve long lasting efficacy and high drug survival in the real world, over 2 years, in biologic-naive patients with Cosentyx.1,3

 

Graphic showing skin clearance rates with Cosentyx were sustained up to 2 years with icons for 86.5% at 1 year and 85.5% at 2 years

Adapted from Bewley A et al. 2019.3

 

‡aPASI ≤3 reflects clear or almost clear skin, or a physician global assessment of 0-1.4
aPASI scores at 12 and 24 months were imputed using data recorded ±90 days of each time point. The fall in patient numbers between years 1 and 2 reflects fewer patients being on treatment long enough to reach the 2-year time point.3

 

How can I help my plaque psoriasis patients LOOK, MOVE and FEEL better?

Explore the data from clinical trials in PsO and PsA to understand how Cosentyx can offer your patients fast and long-lasting relief to help them LOOK, MOVE and FEEL better.

 

 

 

 

aPASI, absolute Psoriasis Area Severity Index; BADBIR, British Association of Dermatologists Biologic and Immunomodulators Register; CRP, C-reactive protein; DMARD, disease-modifying anti-rheumatic drugs; MRI, magnetic resonance imaging; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; PsA, psoriatic arthritis; PsO, plaque psoriasis; ROI, Republic of Ireland.

References     

  1. Yiu ZZN et al. Br J Dermatol 2020; 2020;183(2):294–302
  2. BADBIR. Available at: http://www.badbir.org/Clinicians/Information/StudyInformation/ [Last accessed October 2020].
  3. Bewley A et al. Secukinumab 300 mg demonstrates high and sustained effectiveness in treating patients with moderate to severe plaque psoriasis: Real world evidence from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR). Poster presented at: the 6th Annual Practical Symposium; 8–11 August 2019; Beaver Creek, Colorado, USA.
  4. Amatore F et al. J Eur Acad Dermatol Venereol 2019;33:464–483.
  5. Bissonnette R et al. J Eur Acad Dermatol Venereol 2018;32:1507–1514.
  6. Langley RG et al. N Engl J Med 2014;371(4):326–338.
  7. Thaci D et al. J Am Acad Dermatol 2015;7(3):400–409.
  8. Blauvelt A et al. J Am Acad Dermatol 2017;76(1):60–69.
UK | January 2021 | 100189
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]